When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node. Read more about When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node.
Development and Validation of a Prediction Model for Kidney Failure in Long-Term Survivors of Childhood Cancer. Read more about Development and Validation of a Prediction Model for Kidney Failure in Long-Term Survivors of Childhood Cancer.
Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia. Read more about Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia.
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. Read more about Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial.
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. Read more about Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease.
Reply to G.-F. Li et al, K. Altundag, and N. SG et al. Read more about Reply to G.-F. Li et al, K. Altundag, and N. SG et al.
Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. Read more about Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma.
Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer. Read more about Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer.
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Read more about Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. Read more about Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline.
